Curis, Inc. (CRIS) vs Trevena, Inc. (TRVN)

Curis, Inc. and Trevena, Inc. are both Biotechnology companies. Curis, Inc. and Trevena, Inc. are of similar size ($1.8M and $1.8M). Curis, Inc. grew revenue faster over the last twelve months: −13.4% against −83.0%. Curis, Inc. has the higher net margin (0.00% vs −6,233.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Curis, Inc. leads on 12 and Trevena, Inc. on 4.

Valuation

Metric CRIS TRVN Biotechnology median
P/E n/m n/m 7.88
P/S 0.19 0.02 11.47
P/B 0.38 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 4.67 35.05 10.73
Earnings yield (1,713.25%) (470,400.00%) (28.84%)
Free cash flow yield (1,748.82%) (318,077.37%) (23.03%)

Profitability

Metric CRIS TRVN Biotechnology median
Gross margin 99.52% (190.29%) 65.16%
Operating margin 0.00% (5,879.85%) 0.00%
Net margin 0.00% (6,233.70%) 0.00%
Free cash flow margin 0.00% (4,961.72%) 0.00%
Return on equity 455.35% 344.49% (57.72%)
Return on assets (87.76%) (105.83%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRIS TRVN Biotechnology median
Revenue growth (TTM) (13.43%) (82.97%) 5.64%
EPS growth (last fiscal year) 91.57% 58.37% —
Revenue growth, 5-year CAGR (2.71%) (11.43%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRIS TRVN Biotechnology median
Debt to equity 0.00 (1.41) 0.00
Current ratio 0.49 2.42 4.73
Net debt to EBITDA 0.91 0.06 0.96

Dividend

Metric CRIS TRVN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CRIS TRVN Biotechnology median
Market cap 1.84m 1.81m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack